Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 673790, 5 pages
http://dx.doi.org/10.5402/2011/673790
Clinical Study

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer

1Division of Oncology/Hematology, Department of Medicine, Winthrop-University Hospital, 200 Old Country Road, Suite 450, Mineola, NY 11501, USA
2Division of Immunohistopathology, Department of Pathology, Winthrop-University Hospital, Mineola, NY 11501, USA
3Department of Pathology, Winthrop-University Hospital, Mineola, NY11501, USA

Received 28 March 2011; Accepted 9 May 2011

Academic Editors: Y. Haupt and G. E. Lind

Copyright © 2011 Andrei Dobrescu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Harris, M. E. Lippman, M. Morrow, and C. K. Osborne, Diseases of the Breast, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 3rd edition, 2004.
  2. S. J. London, J. L. Connolly, S. J. Schnitt, and G. A. Colditz, “A prospective study of benign breast disease and the risk of breast cancer,” Journal of the American Medical Association, vol. 267, no. 7, pp. 941–944, 1992. View at Publisher · View at Google Scholar · View at Scopus
  3. W. D. Dupont, F. F. Parl, W. H. Hartmann et al., “Breast cancer risk associated with proliferative breast disease and atypical hyperplasia,” Cancer, vol. 71, no. 4, pp. 1258–1265, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. The Consensus Conference Committee, “Consensus conference on the classification of ductal carcinoma in situ,” Cancer, vol. 80, no. 9, pp. 1798–1802, 1997. View at Google Scholar · View at Scopus
  5. S. R. Wellings and H. M. Jensen, “On the origin and progression of ductal carcinoma in the human breast,” Journal of the National Cancer Institute, vol. 50, no. 5, pp. 1111–1116, 1973. View at Google Scholar · View at Scopus
  6. B. S. Shoker, C. Jarvis, D. R. Sibson, C. Walker, and J. P. Sloane, “Oestrogen receptor expression in the normal and pre-cancerous breast,” Journal of Pathology, vol. 188, no. 3, pp. 237–244, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. F. C. Schmitt, “Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis,” European Journal of Cancer, vol. 31, no. 12, pp. 2049–2052, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. D. D. Giri, S. A. C. Dundas, J. F. Nottingham, and J. C. Underwood, “Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study,” Histopathology, vol. 15, no. 6, pp. 575–584, 1989. View at Google Scholar · View at Scopus
  9. R. Barnes and S. Masood, “Potential value of hormone receptor assay in carcinoma in situ of breast,” American Journal of Clinical Pathology, vol. 94, no. 5, pp. 533–537, 1990. View at Google Scholar · View at Scopus
  10. C. B. Leal, F. C. Schmitt, M. J. Bento, N. C. Maia, and C. S. Lopes, “Ductal carcinoma in situ of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein,” Cancer, vol. 75, no. 8, pp. 2123–2131, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Bose, M. L. Lesser, L. Norton, and P. P. Rosen, “Immunophenotype of intraductal carcinoma,” Archives of Pathology and Laboratory Medicine, vol. 120, no. 1, pp. 81–85, 1996. View at Google Scholar · View at Scopus
  12. L. Pallis, N. Wilking, B. Cedermark, L. E. Rutqvist, and L. Skoog, “Receptors for estrogen and progesterone in breast carcinoma in situ,” Anticancer Research, vol. 12, no. 6, pp. 2113–2115, 1992. View at Google Scholar · View at Scopus
  13. B. Hanstein, S. Djahansouzi, P. Dall, M. W. Beckmann, and H. G. Bender, “Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer,” European Journal of Endocrinology, vol. 150, no. 3, pp. 243–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. S. Tobias, “Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 11, pp. 2112–2119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Malafa, B. Chaudhuri, N. R. Thomford, and P. K. Chaudhuri, “Estrogen receptors in ductal carcinoma in situ of breast,” American Surgeon, vol. 56, no. 7, pp. 436–439, 1990. View at Google Scholar · View at Scopus
  16. M. E. Bur, M. J. Zimarowski, S. J. Schnitt, S. Baker, and R. Lew, “Estrogen receptor immunohistochemistry in carcinoma in situ of the breast,” Cancer, vol. 69, no. 5, pp. 1174–1181, 1992. View at Google Scholar · View at Scopus
  17. G. Arpino, H. L. Weiss, G. M. Clark, S. G. Hilsenbeck, and C. K. Osborne, “Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4687–4694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Swain, J. W. Wilson, E. P. Mamounas et al., “Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 7, pp. 516–523, 2004. View at Google Scholar · View at Scopus
  19. J. A. Martínez-Climent, E. J. Andreu, and F. Prosper, “Somatic stem cells and the origin of cancer,” Clinical and Translational Oncology, vol. 8, no. 9, pp. 647–663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Sleeman and N. Cremers, “New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment,” Clinical and Experimental Metastasis, vol. 24, no. 8, pp. 707–715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Liu, C. Ginestier, E. Charafe-Jauffret et al., “BRCA1 regulates human mammary stem/progenitor cell fate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1680–1685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005. View at Google Scholar
  23. B. Fisher, J. Dignam, N. Wolmark et al., “Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial,” The Lancet, vol. 353, no. 9169, pp. 1993–2000, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Fisher, S. Land, E. Mamounas et al., “Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience,” Seminars in Oncology, vol. 28, no. 4, pp. 400–418, 2001. View at Google Scholar · View at Scopus
  25. D. C. Allred, J. Bryant, S. Land et al., “Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24,” Breast Cancer Research and Treatment, vol. 76, 2002. View at Google Scholar
  26. J. Cuzick, T. Powles, U. Veronesi et al., “Overview of the main outcomes in breast-cancer prevention trials,” The Lancet, vol. 361, no. 9354, pp. 296–300, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin, “National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ,” Clinical Cancer Research, vol. 9, no. 19, part 2, pp. 495S–501S, 2003. View at Google Scholar · View at Scopus
  28. S. S. Badve, F. L. Baehner, R. P. Gray et al., “Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2473–2481, 2008. View at Publisher · View at Google Scholar · View at Scopus